Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials
- My bad: I left out Fox Chase
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Edward Copeland, surgeon and breast cancer expert, dies at 86